Patents by Inventor Bruno Mougin
Bruno Mougin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11299768Abstract: A method for determining a patient's susceptibility of contracting a nosocomial infection that includes obtaining a biological sample from the patient and extracting biological material from the biological sample; preparing a specific reagent of an expression product of at least one target gene selected from S100A9 and S100A8 target genes; and determining the expression of at least one of the target genes S100A9 and S100A8, where overexpression relative to a specified threshold value indicates susceptibility of contracting a nosocomial infection.Type: GrantFiled: January 18, 2010Date of Patent: April 12, 2022Assignees: BIOMERIEUX, HOSPICES CIVILS DE LYONInventors: Marie-Angelique Cazalis, Alain Lepape, Guillaume Monneret, Bruno Mougin, Alexandre Pachot
-
Patent number: 9771621Abstract: The present invention relates to method and kit for performing a colorectal cancer assay. Especially a method including extracting total RNA from a peripheral blood sample obtained from a patient suspected of having or having colorectal cancer; contacting the total RNA, or cDNA or cRNA obtained from the total RNA, with one or more reagents specific for at least one target gene and no more than 100 target genes; and measuring the expression level of the at least one target gene and no more than 100 target genes. The at least one target gene and no more than 100 target genes includes one or more members selected from the group consisting of the KLRB1, KLRC2, KLRC3, KLRD1, KLRK1, CD247, RRAS2, SH2D1B, LCK, MRPS6, SPRY4, CYBB, DUSP2, PDE4D, SH2D2A, GZMB, INSR, ITGAM, VCAN, CD163, P2RY10, CD226, MRPL10, ITPRIPL2, CD2, and NUDT16 genes.Type: GrantFiled: July 18, 2016Date of Patent: September 26, 2017Assignee: BIOMERIEUXInventors: Xun Ye, Fei Wu, Qinghua Xu, Xia Meng, Bruno Mougin, Fang Liu
-
Patent number: 9689041Abstract: The present invention provides a method for determining in vitro, in a peripheral blood sample, the probability for an individual to suffer from a colorectal cancer, using the comparison of the amount of expression products of nucleic acids of genes of the individual to be tested with the amount of expression products of nucleic acids of the same genes obtained from a CRC group of patients constituting the positive control and with the amount of expression products of nucleic acids of the same genes obtained from a CNC group of individuals constituting the negative control; and a kit comprising specific binding partners for said expression products.Type: GrantFiled: March 23, 2012Date of Patent: June 27, 2017Assignee: BIOMERIEUXInventors: Xun Ye, Fei Wu, Qinghua Xu, Fang Liu, Xia Meng, Bruno Mougin
-
Publication number: 20160319371Abstract: The present invention relates to method and kit for performing a colorectal cancer assay. Especially a method including extracting total RNA from a peripheral blood sample obtained from a patient suspected of having or having colorectal cancer; contacting the total RNA, or cDNA or cRNA obtained from the total RNA, with one or more reagents specific for at least one target gene and no more than 100 target genes; and measuring the expression level of the at least one target gene and no more than 100 target genes. The at least one target gene and no more than 100 target genes includes one or more members selected from the group consisting of the KLRB1, KLRC2, KLRC3, KLRD1, KLRK1, CD247, RRAS2, SH2D1B, LCK, MRPS6, SPRY4, CYBB, DUSP2, PDE4D, SH2D2A, GZMB, INSR, ITGAM, VCAN, CD163, P2RY10, CD226, MRPL10, ITPRIPL2, CD2, and NUDT16 genes.Type: ApplicationFiled: July 18, 2016Publication date: November 3, 2016Applicant: BIOMERIEUXInventors: Xun YE, Fei WU, Qinghua XU, Xia MENG, Bruno MOUGIN, Fang LIU
-
Publication number: 20160304944Abstract: A method and kit for discriminating between breast cancer and benign breast disease by the determination of the expression level of at least one target gene having a nucleic acid sequence selected from the nucleic acid sequences set forth in SEQ ID NOs: 1, 2 or 3, 4 and 5 or 6 to obtain an expression profile for the patient, and the comparison of the expression profile of the patient with expression profiles of target genes from patients previously clinically classified as breast cancer and expression profiles of target genes from patients previously clinically classified as benign breast disease.Type: ApplicationFiled: June 30, 2016Publication date: October 20, 2016Applicant: BIOMERIEUXInventors: Xun YE, Fei WU, Qinghua XU, Xia MENG, Bruno MOUGIN
-
Patent number: 9422598Abstract: A method and kit for the prognosis of colorectal cancer where the method includes the steps of: a) obtaining a peripheral blood sample and extracting total RNA from the sample, b) contacting the total RNA with at least one reagent specific for at least one NK cell gene and no more than 25 specific reagents for 25 NK cell genes, c) determining the expression level of at least one and at most 25 NK cell genes to obtain an expression profile for the patient, d) analyzing the expression profile with expression profiles previously clinically classified as a good prognosis and as a poor prognosis, wherein if the expression profile is clustered with the poor prognosis profiles, then the patient is determined to have a poor prognosis, and if the expression profile is clustered with the good prognosis profiles, then the patient is determined to have a good prognosis.Type: GrantFiled: June 4, 2010Date of Patent: August 23, 2016Assignee: BIOMERIEUXInventors: Xun Ye, Fei Wu, Qinghua Xu, Xia Meng, Bruno Mougin, Fang Liu
-
Patent number: 9410188Abstract: A method and kit are related to discriminating between breast cancer and benign breast disease by the determination of the expression level of at least one target gene including a nucleic acid sequence selected from the nucleic acid sequences set forth in SEQ ID NOs: 1, 2 or 3, 4 and 5 or 6 to obtain an expression profile for the patient, and the comparison of the expression profile of the patient with expression profiles of target genes from patients previously clinically classified as breast cancer and expression profiles of target genes from patients previously clinically classified as benign breast disease.Type: GrantFiled: May 28, 2010Date of Patent: August 9, 2016Assignee: BIOMERIEUXInventors: Xun Ye, Fei Wu, Qinghua Xu, Xia Meng, Bruno Mougin
-
Publication number: 20140057802Abstract: The present invention provides a method for determining in vitro, in a peripheral blood sample, the probability for an individual to suffer from a colorectal cancer, using the comparison of the amount of expression products of nucleic acids of genes of the individual to be tested with the amount of expression products of nucleic acids of the same genes obtained from a CRC group of patients constituting the positive control and with the amount of expression products of nucleic acids of the same genes obtained from a CNC group of individuals constituting the negative control; and a kit comprising specific binding partners for said expression products.Type: ApplicationFiled: March 23, 2012Publication date: February 27, 2014Applicant: BIOMERIEUXInventors: Xun Ye, Fei Wu, Qinghua Xu, Fang Liu, Xia Meng, Bruno Mougin
-
Publication number: 20130210670Abstract: Method for determining a level of activity of a biological pathway from a biological sample of a patient suffering from a pathology, the method comprising the steps of: measuring the level of expression of at least three genes from a group of individuals, control individuals or patients, for which the biological pathway is inactive, the at least three genes being associated to the biological pathway, for establishing a negative reference, and measuring level of expression of the at least three genes from a group of individuals, control individuals or patients, for which the biological pathway is active, for establishing a positive reference, and measuring the level of expression of the at least three genes of the patient in the sample.Type: ApplicationFiled: September 19, 2011Publication date: August 15, 2013Applicants: Hospices Civils De Lyon, BiomerieuxInventors: Pierre Miossec, Bruno Mougin, Malick Paye, Frederic Reynier
-
Publication number: 20130072401Abstract: A method and kit for the prognosis of colorectal cancer where the method includes the steps of: a) obtaining a peripheral blood sample and extracting total RNA from the sample, b) contacting the total RNA with at least one reagent specific for at least one NK cell gene and no more than 25 specific reagents for 25 NK cell genes, c) determining the expression level of at least one and at most 25 NK cell genes to obtain an expression profile for the patient, d) analyzing the expression profile with expression profiles previously clinically classified as a good prognosis and as a poor prognosis, wherein if the expression profile is clustered with the poor prognosis profiles, then the patient is determined to have a poor prognosis, and if the expression profile is clustered with the good prognosis profiles, then the patient is determined to have a good prognosis.Type: ApplicationFiled: June 4, 2010Publication date: March 21, 2013Applicant: BIOMERIEUXInventors: Xun Ye, Fei Wu, Qinghua Xu, Xia Meng, Bruno Mougin, Fang Liu
-
Publication number: 20130072399Abstract: A method and kit are related to discriminating between breast cancer and benign breast disease by the determination of the expression level of at least one target gene including a nucleic acid sequence selected from the nucleic acid sequences set forth in SEQ ID NOs: 1, 2 or 3, 4 and 5 or 6 to obtain an expression profile for the patient, and the comparison of the expression profile of the patient with expression profiles of target genes from patients previously clinically classified as breast cancer and expression profiles of target genes from patients previously clinically classified as benign breast disease.Type: ApplicationFiled: May 28, 2010Publication date: March 21, 2013Applicant: BIOMERIEUXInventors: Xun Ye, Fei Wu, Qinghua Xu, Xia Meng, Bruno Mougin
-
Publication number: 20110250592Abstract: A method for determining a patient's susceptibility of contracting a nosocomial infection that includes obtaining a biological sample from the patient and extracting biological material from the biological sample; preparing a specific reagent of an expression product of at least one target gene selected from S100A9 and S100A8 target genes; and determining the expression of at least one of the target genes S100A9 and S100A8, where overexpression relative to a specified threshold value indicates susceptibility of contracting a nosocomial infection.Type: ApplicationFiled: January 18, 2010Publication date: October 13, 2011Applicants: HOSPICES CIVILS DE LYON (HCL), BIOMERIEUXInventors: Marie-Angelique Cazalis, Alain Lepape, Guillaume Monneret, Bruno Mougin, Alexandre Pachot
-
Publication number: 20100267014Abstract: The present invention concerns an in vitro method for determining, from a biological sample, the response to a patient suffering from rheumatoid arthritis to a treatment directed against a cytokine involved in the inflammatory process of the disease, characterized in that it consists in measuring the expression of the gene encoding synoviolin.Type: ApplicationFiled: February 28, 2006Publication date: October 21, 2010Applicant: HOSPICES CIVILS DE LYONInventors: Myew-Ling Toh, Pierre Miossec, Jean-Luc Blond, Bruno Mougin
-
Publication number: 20090269744Abstract: The present application concerns methods and compositions which can be used to detect cancer in mammals, in particular in humans. It notably describes serum markers of cancers and their uses in diagnosis methods. It also concerns tools and/or kits which can be used to implement these methods (reagents, probes, primers, antibodies, chips, cells, etc.), their preparation and their uses. The invention can be used to detect the presence or the progression of a cancer, particularly breast cancer, including at an early stage.Type: ApplicationFiled: October 26, 2006Publication date: October 29, 2009Applicants: EXONHIT THERAPEUTICS SA, BIOMERIEUX SAInventors: Alexander Krause, Philippe Leissner, Malick Paye, Bruno Mougin, Fabien Schweighoffer, Laurent Bracco
-
Publication number: 20090123924Abstract: The invention relates to a method for the in vitro diagnosis of breast cancer in a patient who may be suffering from a breast cancer, characterized in that it comprises the following steps: a) biological material is extracted from a biological sample taken from the patient, b) the biological material is brought into contact with at least 8 specific reagents chosen from the specific reagents for the target genes with a nucleic sequence having any one of SEQ ID Nos. 1 to 8, c) the expression of said target genes is determined.Type: ApplicationFiled: July 5, 2006Publication date: May 14, 2009Applicant: BiomerieuxInventors: Alexander Krause, Philippe Leissner, Bruno Mougin, Malick Paye
-
Publication number: 20070134674Abstract: The present invention relates to a method for the prognosis and/or diagnosis of a cancer using a biological sample taken from a patient, according to which the expression of the twist gene is determined. The invention also relates to the use of at least one inhibitor of twist gene expression for the manufacture of a medicament for combating cancer.Type: ApplicationFiled: April 6, 2005Publication date: June 14, 2007Inventors: Bruno Mougin, Alexander Krause, Alain Puisieux, Sandrine Valsesia-Wittmann
-
Patent number: 7060438Abstract: A patient's genetic predisposition to a disease may be analyzed by placing, in the presence of probes, at least one type of amplicon, derived from the amplification of at least one polymorphic region of nucleic acid from the patient. The polymorphic region is a polymorphic region of interest with respect to the disease(s) being sought.Type: GrantFiled: May 19, 2000Date of Patent: June 13, 2006Assignee: Bio MerieuxInventors: Bruno Mougin, Jean-Marie Tiercy
-
Publication number: 20040033516Abstract: This invention concerns a method for testing a subject's predisposition to insulin-dependent diabetes.Type: ApplicationFiled: May 16, 2003Publication date: February 19, 2004Inventor: Bruno Mougin
-
Publication number: 20020172985Abstract: The present invention provides a reagent for the detection or monitoring of a Toxoplasma gondii infection, which includes as a reactive substance a truncated Toxoplasma gondii P30 protein in which all of the hydrophobic C-terminal region of the native protein starting with the amino acid positioned after the amino acid 299 (SEQ ID NO: 1) has been deleted and all of the region of the native protein having the sequence starting with amino acid 31 and ending with the amino acid 299 (SEQ ID NO: 1) is contained.Type: ApplicationFiled: May 4, 2001Publication date: November 21, 2002Inventors: Eric Jacobs, Nathalie Silvestre, Bruno Mougin, Odette Bissardon, Michel Jolivet
-
Patent number: 6372443Abstract: The present invention provides a reagent for the detection or monitoring of a Toxoplasma gondii infection, which includes as a reactive substance a truncated Toxoplasma gondii P30 protein in which all of the hydrophobic C-terminal region of the native protein starting with the amino acid positioned after the amino acid 299 (SEQ ID NO: 1) has been deleted and all of the region of the native protein having the sequence starting with amino acid 31 and ending with the amino acid 299 (SEQ ID NO: 1) is contained. The present invention further describes methods of screening for anti-Toxoplasma antibodies in a biological sample.Type: GrantFiled: March 13, 1996Date of Patent: April 16, 2002Assignees: Transgene S.A., BiomerieuxInventors: Eric Jacobs, Nathalie Silvestre, Bruno Mougin, Odette Bissardon, Michel Jolivet